U.S. Markets closed
  • S&P 500

    3,310.11
    +39.08 (+1.19%)
     
  • Dow 30

    26,659.11
    +139.16 (+0.52%)
     
  • Nasdaq

    11,185.59
    +180.72 (+1.64%)
     
  • Russell 2000

    1,561.58
    +18.30 (+1.19%)
     
  • Crude Oil

    36.13
    -0.04 (-0.11%)
     
  • Gold

    1,868.40
    +0.40 (+0.02%)
     
  • Silver

    23.39
    +0.02 (+0.11%)
     
  • EUR/USD

    1.1684
    -0.0066 (-0.5608%)
     
  • 10-Yr Bond

    0.8350
    +0.0540 (+6.91%)
     
  • Vix

    37.59
    -2.69 (-6.68%)
     
  • GBP/USD

    1.2928
    -0.0059 (-0.4576%)
     
  • USD/JPY

    104.5310
    +0.2300 (+0.2205%)
     
  • BTC-USD

    13,458.11
    -84.81 (-0.63%)
     
  • CMC Crypto 200

    264.05
    +21.37 (+8.80%)
     
  • FTSE 100

    5,581.75
    -1.05 (-0.02%)
     
  • Nikkei 225

    23,331.94
    -86.57 (-0.37%)
     

Amarin (AMRN) Gains As Market Dips: What You Should Know

Zacks Equity Research

Amarin (AMRN) closed at $17.35 in the latest trading session, marking a +1.46% move from the prior day. This move outpaced the S&P 500's daily loss of 0.27%. Elsewhere, the Dow lost 0.41%, while the tech-heavy Nasdaq added 0.09%.

Heading into today, shares of the biopharmaceutical company had gained 2.95% over the past month, lagging the Medical sector's gain of 3.32% and the S&P 500's gain of 6.26% in that time.

Wall Street will be looking for positivity from AMRN as it approaches its next earnings report date. The company is expected to report EPS of -$0.05, up 37.5% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $74.45 million, up 38.2% from the year-ago period.

Investors should also note any recent changes to analyst estimates for AMRN. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 13.46% higher. AMRN is holding a Zacks Rank of #3 (Hold) right now.

The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 67, which puts it in the top 27% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Amarin Corporation PLC (AMRN) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.